Epidemiology of Hepatitis C Virus. A Battle on New Frontiers

Gastroenterology Clinics of North America

Volumn 44, Issue 4, 2015, Pages 699-716

  Shire, Norah J ^a   Sherman, Kenneth E ^b  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Acute HCV; Co infection; HCV epidemiology; Incidence; Prevalence

Indexed keywords

AUSTRALIA; BLOOD TRANSFUSION; BRAZIL; CHINA; CIRCUMCISION; CLINICAL EVALUATION; DENTAL PROCEDURE; ECONOMIC ASPECT; EGYPT; EUROPE; GEOGRAPHY; HEMOPHILIA; HEPATITIS C; HEPATITIS C VIRUS; HOME DELIVERY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INDIA; INFECTION PREVENTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; JAPAN; MEN WHO HAVE SEX WITH MEN; MEXICO; MORBIDITY; MORTALITY; NORTH AMERICA; PAKISTAN; POLAND; POLITICS; PREVALENCE; PRISONER; REVIEW; RUSSIAN FEDERATION; SURGICAL TECHNIQUE; THAILAND; UNITED STATES; UNSAFE SEX; VETERAN; VIET NAM; VIRAL CONTAMINATION; VIRUS IDENTIFICATION; VIRUS TRANSMISSION; DEVELOPED COUNTRY; DEVELOPING COUNTRY; HEALTH; HEPATITIS C, CHRONIC; TRANSMISSION;

DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; GLOBAL HEALTH; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; PREVALENCE;

EID: 84947553516     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2015.07.002     Document Type: Review

References (106)

1. Denniston M.M., Jiles R.B., Drobeniuc J., et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014, 160(5):293-300.
2. Armstrong G.L., Wasley A., Simard E.P., et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144(10):705-714.
3. World Health Organization. Hepatitis C fact sheet. 2014. Available at: . Accessed April 14, 2015. http://www.who.int/mediacentre/factsheets/fs164/en/.
4. Micallef J.M., Kaldor J.M., Dore G.J. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006, 13(1):34-41.
5. Thein H.H., Yi Q., Dore G.J., et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008, 48(2):418-431.
6. Wong R.J., Aguilar M., Cheung R., et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015, 148(3):547-555.
7. Lozano R., Naghavi M., Foreman K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet 2012, 380(9859):2095-2128.
8. Alter H.J., Holland P.V., Morrow A.G., et al. Clinical and serological analysis of transfusion-associated hepatitis. Lancet 1975, 2(7940):838-841.
9. Dienstag J.L., Purcell H.R., Alter H.J., et al. Non-A, non-B post-transfusion hepatitis. Lancet 1977, 1(8011):560-562.
10. Hoofnagle J.H., Gerety R.J., Tabor E., et al. Transmission of non-A, non-B hepatitis. Ann Intern Med 1977, 87(1):14-20.
11. Aach R.D., Szmuness W., Mosley J.W., et al. Serum alanine aminotransferase of donors in relation to the risk of non-A,non-B hepatitis in recipients: the transfusion-transmitted viruses study. N Engl J Med 1981, 304(17):989-994.
12. Villarejos V.M., Visona K.A., Eduarte C.A., et al. Evidence for viral hepatitis other than type A or type B among persons in Costa Rica. N Engl J Med 1975, 293(26):1350-1352.
13. Caredda F., d'Arminio Monforte A., Rossi E., et al. Non-A, non-B hepatitis in Milan. Lancet 1981, 2(8236):48.
14. Hornbrook M.C., Dodd R.Y., Jacobs P., et al. Reducing the incidence of non-A, non-B post-transfusion hepatitis by testing donor blood for alanine aminotransferase: economic considerations. N Engl J Med 1982, 307(21):1315-1321.
15. Seeff L.B., Zimmerman H.J., Wright E.C., et al. A randomized, double blind controlled trial of the efficacy of immune serum globulin for the prevention of post-transfusion hepatitis. A Veterans Administration cooperative study. Gastroenterology 1977, 72(1):111-121.
16. Kim H.C., Saidi P., Ackley A.M., et al. Prevalence of type B and non-A, non-B hepatitis in hemophilia: relationship to chronic liver disease. Gastroenterology 1980, 79(6):1159-1164.
17. Tabor E., Seeff L.B., Gerety R.J. Chronic non-A, non-B hepatitis carrier state: transmissible agent documented in one patient over a six-year period. N Engl J Med 1980, 303(3):140-143.
18. Choo Q.L., Kuo G., Weiner A.J., et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244(4902):359-362.
19. Takeuchi K., Kubo Y., Boonmar S., et al. Nucleotide sequence of core and envelope genes of the hepatitis C virus genome derived directly from human healthy carriers. Nucleic Acids Res 1990, 18(15):4626.
20. Kuo G., Choo Q.L., Alter H.J., et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989, 244(4902):362-364.
21. Miyamura T., Saito I., Katayama T., et al. Detection of antibody against antigen expressed by molecularly cloned hepatitis C virus cDNA: application to diagnosis and blood screening for posttransfusion hepatitis. Proc Natl Acad Sci U S A 1990, 87(3):983-987.
22. Weiner A.J., Kuo G., Bradley D.W., et al. Detection of hepatitis C viral sequences in non-A, non-B hepatitis. Lancet 1990, 335(8680):1-3.
23. Kato N., Yokosuka O., Omata M., et al. Detection of hepatitis C virus ribonucleic acid in the serum by amplification with polymerase chain reaction. J Clin Invest 1990, 86(5):1764-1767.
24. Sanchez-Tapias J.M., Barrera J.M., Costa J., et al. Hepatitis C virus infection in patients with nonalcoholic chronic liver disease. Ann Intern Med 1990, 112(12):921-924.
25. Brettler D.B., Alter H.J., Dienstag J.L., et al. Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients. Blood 1990, 76(1):254-256.
26. Troisi C.L., Hollinger F.B., Hoots W.K., et al. A multicenter study of viral hepatitis in a United States hemophilic population. Blood 1993, 81(2):412-418.
27. Makris M., Preston F.E., Triger D.R., et al. Hepatitis C antibody and chronic liver disease in haemophilia. Lancet 1990, 335(8698):1117-1119.
28. Eyster M.E., Schaefer J.H., Ragni M.V., et al. Changing causes of death in Pennsylvania's hemophiliacs 1976 to 1991: impact of liver disease and acquired immunodeficiency syndrome. Blood 1992, 79(9):2494-2495.
29. Jeffers L.J., Perez G.O., de Medina M.D., et al. Hepatitis C infection in two urban hemodialysis units. Kidney Int 1990, 38(2):320-322.
30. Ha S.K., Park J.H., Choi W.C., et al. Hepatitis C infection in hemodialysis units. Korean J Intern Med 1990, 5(2):83-86.
31. Bell J., Batey R.G., Farrell G.C., et al. Hepatitis C virus in intravenous drug users. Med J Aust 1990, 153(5):274-276.
32. van den Hoek J.A., van Haastrecht H.J., Goudsmit J., et al. Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam. J Infect Dis 1990, 162(4):823-826.
33. Sanchez-Quijano A., Rey C., Aguado I., et al. Hepatitis C virus infection in sexually promiscuous groups. Eur J Clin Microbiol Infect Dis 1990, 9(8):610-612.
34. Laurent C., Henzel D., Mulanga-Kabeya C., et al. Seroepidemiological survey of hepatitis C virus among commercial sex workers and pregnant women in Kinshasa, Democratic Republic of Congo. Int J Epidemiol 2001, 30(4):872-877.
35. Hadush H., Gebre-Selassie S., Mihret A. Hepatitis C virus and human immunodeficiency virus coinfection among attendants of voluntary counseling and testing centre and HIV follow up clinics in Mekelle hospital. Pan Afr Med J 2013, 14:107.
36. Alter M.J., Hadler S.C., Judson F.N., et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990, 264(17):2231-2235.
37. Yu M.C., Tong M.J., Coursaget P., et al. Prevalence of hepatitis B and C viral markers in black and white patients with hepatocellular carcinoma in the United States. J Natl Cancer Inst 1990, 82(12):1038-1041.
38. Di Bisceglie A.M., Order S.E., Klein J.L., et al. The role of chronic viral hepatitis in hepatocellular carcinoma in the United States. Am J Gastroenterol 1991, 86(3):335-338.
39. Saito I., Miyamura T., Ohbayashi A., et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A 1990, 87(17):6547-6549.
40. Soucie J.M., Richardson L.C., Evatt B.L., et al. Risk factors for infection with HBV and HCV in a large cohort of hemophiliac males. Transfusion 2001, 41(3):338-343.
41. Stevens C.E., Taylor P.E., Pindyck J., et al. Epidemiology of hepatitis C virus. A preliminary study in volunteer blood donors. JAMA 1990, 263(1):49-53.
42. Gower E., Estes C., Blach S., et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014, 61(1 Suppl):S45-S57.
43. Alter M.J. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007, 13(17):2436-2441.
44. Alter M.J., Kruszon-Moran D., Nainan O.V., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999, 341(8):556-562.
45. Backus L.I., Belperio P.S., Loomis T.P., et al. Impact of race/ethnicity and gender on HCV screening and prevalence among U.S. veterans in Department of Veterans Affairs care. Am J Public Health 2014, 104(Suppl 4):S555-S561.
46. Chak E., Talal A.H., Sherman K.E., et al. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011, 31(8):1090-1101.
47. Williams I.T., Bell B.P., Kuhnert W., et al. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. Arch Intern Med 2011, 171(3):242-248.
48. Suryaprasad A.G., White J.Z., Xu F., et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis 2014, 59(10):1411-1419.
49. Tanaka Y., Hanada K., Mizokami M., et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A 2002, 99(24):15584-15589.
50. Tanaka J., Koyama T., Mizui M., et al. Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale. Intervirology 2011, 54(4):185-195.
51. Chung H., Ueda T., Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology 2010, 53(1):39-43.
52. Toyoda H., Kumada T., Takaguchi K., et al. Changes in hepatitis C virus genotype distribution in Japan. Epidemiol Infect 2014, 142(12):2624-2628.
53. Tanaka H., Imai Y., Hiramatsu N., et al. Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. Ann Intern Med 2008, 148(11):820-826.
54. Palmateer N., Hutchinson S., McAllister G., et al. Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data. J Viral Hepat 2014, 21(1):25-32.
55. Hahne S.J., Veldhuijzen I.K., Wiessing L., et al. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis 2013, 13:181.
56. Spada E., Mele A., Mariano A., et al. Risk factors for and incidence of acute hepatitis C after the achievement of blood supply safety in Italy: results from the national surveillance system. J Med Virol 2013, 85(3):433-440. SEIEVA Collaborating Group.
57. Vermehren J., Schlosser B., Domke D., et al. High prevalence of anti-HCV antibodies in two metropolitan emergency departments in Germany: a prospective screening analysis of 28,809 patients. PLoS One 2012, 7(7):e41206.
58. Hope V., Parry J.V., Marongui A., et al. Hepatitis C infection among recent initiates to injecting in England 2000-2008: is a national hepatitis C action plan making a difference?. J Viral Hepat 2012, 19(1):55-64.
59. Flisiak R., Halota W., Horban A., et al. Prevalence and risk factors of HCV infection in Poland. Eur J Gastroenterol Hepatol 2011, 23(12):1213-1217.
60. Wiessing L., Ferri M., Grady B., et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One 2014, 9(7):e103345.
61. Cornberg M., Razavi H.A., Alberti A., et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011, 31(Suppl 2):30-60.
62. Paquet C., Babes V.T., Drucker J., et al. Viral hepatitis in Bucharest. Bull World Health Organ 1993, 71(6):781-786.
63. The Kirby Institute HIV, viral hepatitis and sexually transmissible infections in Australia annual surveillance report 2014 2014, 2052. The Kirby Institute, UNSW, Sydney (Australia).
64. Maher L., Jalaludin B., Chant K.G., et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction 2006, 101(10):1499-1508.
65. Topp L., Day C., Degenhardt L. Changes in patterns of drug injection concurrent with a sustained reduction in the availability of heroin in Australia. Drug Alcohol Depend 2003, 70(3):275-286.
66. Song Y., Bian Y., Petzold M., et al. Prevalence and trend of major transfusion-transmissible infections among blood donors in Western China, 2005 through 2010. PLoS One 2014, 9(4):e94528.
67. Huang P., Zhu L.G., Zhai X.J., et al. Hepatitis C virus infection and risk factors in the general population: a large community-based study in Eastern China, 2011-2012. Epidemiol Infect 2015, 1-10. [Epub ahead of print].
68. Kuang Y.Q., Yan J., Li Y., et al. Molecular epidemiologic characterization of a clustering HCV infection caused by inappropriate medical care in Heyuan city of Guangdong, China. PLoS One 2013, 8(12):e82304.
69. Piao H.X., Yang A.T., Sun Y.M., et al. Increasing newly diagnosed rate and changing risk factors of HCV in Yanbian Prefecture, a high endemic area in China. PLoS One 2014, 9(1):e86190.
70. Dong Y., Qiu C., Xia X., et al. Hepatitis B virus and hepatitis C virus infection among HIV-1-infected injection drug users in Dali, China: prevalence and infection status in a cross-sectional study. Arch Virol 2015, 160(4):929-936.
71. Xiaoli W., Lirong W., Xueliang W., et al. Risk factors of hepatitis C virus infection in drug users from eleven methadone maintenance treatment clinics in Xi'an, China. Hepat Mon 2014, 14(11):e19601.
72. Zhou W., Wang X., Zhou S., et al. Hepatitis C seroconversion in methadone maintenance treatment programs in Wuhan, China. Addiction 2015, 110(5):796-802.
73. Chen Y., Shen Z., Morano J.P., et al. Bridging the epidemic: a comprehensive analysis of prevalence and correlates of HIV, hepatitis C, and syphilis, and infection among female sex workers in Guangxi province, China. PLoS One 2015, 10(2):e0115311.
74. Sievert W., Altraif I., Razavi H.A., et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011, 31(Suppl 2):61-80.
75. Puri P., Anand A.C., Saraswat V.A., et al. Consensus statement of HCV task force of the Indian National Association for Study of the Liver (INASL). Part I: status report of HCV infection in India. J Clin Exp Hepatol 2014, 4(2):106-116.
76. Umar M., Bushra H.T., Ahmad M., et al. Hepatitis C in Pakistan: a review of available data. Hepat Mon 2010, 10(3):205-214.
77. Centers for Disease Control and Prevention (CDC) Establishment of a viral hepatitis surveillance system-Pakistan, 2009-2011. MMWR Morb Mortal Wkly Rep 2011, 60(40):1385-1390.
78. Altaf A., Shah S.A., Shaikh K., et al. Lessons learned from a community based intervention to improve injection safety in Pakistan. BMC Res Notes 2013, 6:159.
79. Guerra J., Garenne M., Mohamed M.K., et al. HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat 2012, 19(8):560-567.
80. Miller F.D., Abu-Raddad L.J. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proc Natl Acad Sci U S A 2010, 107(33):14757-14762.
81. Frank C., Mohamed M.K., Strickland G.T., et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000, 355(9207):887-891.
82. Derbala M., Chandra P., Amer A., et al. Reexamination of the relationship between the prevalence of hepatitis C virus and parenteral antischistosomal therapy among Egyptians resident in Qatar. Clin Exp Gastroenterol 2014, 7:427-433.
83. Mohsen A., Bernier A., LeFouler L., et al. Hepatitis C virus acquisition among Egyptians: analysis of a 10-year surveillance of acute hepatitis C. Trop Med Int Health 2015, 20(1):89-97.
84. El-Ghitany E.M., Abdel Wahab M.M., Abd El-Wahab E.W., et al. A comprehensive hepatitis C virus risk factors meta-analysis (1989-2013): do they differ in Egypt?. Liver Int 2015, 35(2):489-501.
85. Layden J.E., Phillips R., Opare-Sem O., et al. Hepatitis C in sub-Saharan Africa: urgent need for attention. Open Forum Infect Dis 2014, 1(2):ofu065.
86. Layden J.E., Phillips R.O., Owusu-Ofori S., et al. High frequency of active HCV infection among seropositive cases in West Africa and evidence for multiple transmission pathways. Clin Infect Dis 2015, 60(7):1033-1041.
87. Hatzakis A., Chulanov V., Gadano A.C., et al. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2. J Viral Hepat 2015, 22(Suppl 1):26-45.
88. Center for Disease Analysis. Hep C epidemiology-summary slides. 2015. Available at: . Accessed April 7, 2015. http://www.centerforda.com/downloads.htm.
89. van de Laar T.J., Matthews G.V., Prins M., et al. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS 2010, 24(12):1799-1812.
90. Obermeier M., Ingiliz P., Weitner L., et al. Acute hepatitis C in persons infected with the human immunodeficiency virus (HIV): the "real-life setting" proves the concept. Eur J Med Res 2011, 16(5):237-242.
91. Lambers F.A., Prins M., Thomas X., et al. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. AIDS 2011, 25(17):F21-F27.
92. Urbanus A.T., van de Laar T.J., Stolte I.G., et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS 2009, 23(12):F1-F7.
93. Centers for Disease Control and Prevention (CDC) Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men-New York city, 2005-2010. MMWR Morb Mortal Wkly Rep 2011, 60(28):945-950.
94. McFaul K., Maghlaoui A., Nzuruba M., et al. Acute hepatitis C infection in HIV-negative men who have sex with men. J Viral Hepat 2015, 22(6):535-538.
95. Fierer D.S., Uriel A.J., Carriero D.C., et al. Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis 2008, 198(5):683-686.
96. Osinusi A., Kleiner D., Wood B., et al. Rapid development of advanced liver fibrosis after acquisition of hepatitis C infection during primary HIV infection. AIDS Patient Care STDS 2009, 23(6):403-406.
97. Ward C., Lee V. Experience of acute hepatitis C and HIV co-infection in an inner city clinic in the UK. J Int AIDS Soc 2014, 17(4 Suppl 3):19639.
98. Orsetti E., Staffolani S., Gesuita R., et al. Changing characteristics and risk factors of patients with and without incident HCV infection among HIV-infected individuals. Infection 2013, 41(5):987-990.
99. Schmidt A.J., Rockstroh J.K., Vogel M., et al. Trouble with bleeding: risk factors for acute hepatitis C among HIV-positive gay men from Germany-a case-control study. PLoS One 2011, 6(3):e17781.
100. Vanhommerig J.W., Thomas X.V., van der Meer J.T., et al. Hepatitis C virus (HCV) antibody dynamics following acute HCV infection and reinfection among HIV-infected men who have sex with men. Clin Infect Dis 2014, 59(12):1678-1685.
101. Ingiliz P., Krznaric I., Stellbrink H.J., et al. Multiple hepatitis C virus (HCV) reinfections in HIV-positive men who have sex with men: no influence of HCV genotype switch or interleukin-28B genotype on spontaneous clearance. HIV Med 2014, 15(6):355-361.
102. Martin T.C., Martin N.K., Hickman M., et al. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. AIDS 2013, 27(16):2551-2557.
103. Sherman K.E., Rouster S.D., Chung R.T., et al. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002, 34(6):831-837.
104. Benhamou Y., Bochet M., Di Martino V., et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999, 30(4):1054-1058.
105. Centers for Disease Control and Prevention (CDC) Hepatitis C virus infection among adolescents and young adults: Massachusetts, 2002-2009. MMWR Morb Mortal Wkly Rep 2011, 60(17):537-541.
106. Jennings C.L., Sherman K.E. Hepatitis C and HIV co-infection: new drugs in practice and in the pipeline. Curr HIV/AIDS Rep 2012, 9(3):231-237.